{"url_path":"/sec/dyn/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1818794/0001193125-26-254597-index.html","accession_number":"0001193125-26-254597","cik":"0001818794","ticker":"DYN","issuer_name":"Dyne Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818794/0001193125-26-254597-index.html","primary_entity_key":"0001818794","primary_entity_name":"Dyne Therapeutics, Inc."},"word_count":90,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit No.\n\nDescription\n\n \n\n \n\n \n\n99.1\n\n104\n\n[Press Release issued by Dyne Therapeutics, Inc. on June 3, 2026](dyn-ex99_1.htm)\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDYNE THERAPEUTICS, INC.\n\n \n\n \n\n \n\nDate: June 3, 2026\n\nBy:\n\n/s/ John G. Cox\n\n \n\n \n\nName:\n\nJohn G. Cox\n\n \n\n \n\nTitle:\n\nPresident and Chief Executive Officer"}